BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

Conditions: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Hairy Cell Leukemia; Multiple Myeloma
Interventions: Biological: LMY-922
Sponsors: Luminary Therapeutics
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 2, 2026Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments